Skip to main content

Table 4 Median MSQ score at baseline and follow up in months. Median difference in MSQ compared to baseline and percentage in MSQ compared to baseline. Proportion of patients contributing to the data

From: Medium-term real-world data for erenumab in 177 treatment resistant or difficult to treat chronic migraine patients: persistence and patient reported outcome measures after 17–30 months

Time

Baseline Median (Total)

Baseline Median (Tested)

MSQ Median After

Change (%)

No. of patients completing questionnaires (No. of patients on treatment)

Zero

63

63

  

177 (177)

1 to 6

63

63

46.5

−16.5 (26%)

135 (161)

7 to 12

63

63

41

−22 (35%)

93 (145)

13 to 18

62

57.5

36

−21.5 (37%)

48 (109)

19 to 24

63

61

38

−23 (38%)

55 (97)

25 to 30

61

66

36

−30 (45%)

35 (54)